• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌患者治疗进展:症状改善与生存时间延长。圣安东尼奥药物研发团队。

Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.

作者信息

Von Hoff D D, Goodwin A L, Garcia L

机构信息

Institute for Drug Development, Cancer Therapy & Research Center, San Antonio, Texas 78245, USA.

出版信息

Br J Cancer. 1998;78 Suppl 3(Suppl 3):9-13. doi: 10.1038/bjc.1998.748.

DOI:10.1038/bjc.1998.748
PMID:9717985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2062801/
Abstract

Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside analogue gemcitabine (GEMZAR) has been shown to provide clinical benefit for patients (decreased pain and improved performance status) as well as to improve the time to tumour progression and survival for patients with the disease. There are also other new agents that are presented in this discussion, such as the multi-targeted antifolate MTA, capecitabine and the ONYX-015 adenovirus, which replicates in, and kills, only p53-abnormal cells, which have the potential to have an impact on this terrible disease.

摘要

在美国和欧洲,胰腺癌是导致男性和女性癌症死亡的主要原因。这种疾病会引发疼痛,并对患者的身体状况产生重大影响。在一项与5-氟尿嘧啶对比的随机试验中,新型核苷类似物吉西他滨(健择)已被证明能为患者带来临床益处(减轻疼痛并改善身体状况),还能延长该疾病患者的肿瘤进展时间并提高生存率。本次讨论中还提到了其他一些新型药物,比如多靶点抗叶酸药物MTA、卡培他滨以及ONYX - 015腺病毒,后者仅在p53异常的细胞中复制并将其杀死,这些药物都有可能对这种可怕的疾病产生影响。

相似文献

1
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.胰腺癌患者治疗进展:症状改善与生存时间延长。圣安东尼奥药物研发团队。
Br J Cancer. 1998;78 Suppl 3(Suppl 3):9-13. doi: 10.1038/bjc.1998.748.
2
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.吉西他滨治疗晚期胰腺癌:随机试验的比较分析
Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16. doi: 10.1053/sonc.2002.37372.
3
Pemetrexed in pancreatic cancer.培美曲塞用于胰腺癌治疗
Semin Oncol. 2002 Dec;29(6 Suppl 18):49-53. doi: 10.1053/sonc.2002.37472.
4
Chemotherapy for advanced pancreatic cancer.晚期胰腺癌的化疗
Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):327-48. doi: 10.1016/j.bpg.2005.10.003.
5
Advanced pancreatic cancer: is there a role for combination therapy?晚期胰腺癌:联合治疗是否有作用?
Expert Rev Anticancer Ther. 2003 Oct;3(5):729-39. doi: 10.1586/14737140.3.5.729.
6
[Gemcitabine and pemetrexed update].[吉西他滨与培美曲塞的更新情况]
Bull Cancer. 2007;94 Spec No Actualites:S83.
7
The role of pemetrexed in the treatment of gastrointestinal malignancy.培美曲塞在胃肠道恶性肿瘤治疗中的作用。
Clin Colorectal Cancer. 2004 Sep;4(3):190-5. doi: 10.3816/ccc.2004.n.019.
8
The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.培美曲塞(力比泰)与吉西他滨在非小细胞肺癌中的新作用。
Semin Oncol. 2003 Aug;30(4 Suppl 10):37-44. doi: 10.1016/s0093-7754(03)00284-7.
9
The pemetrexed/gemcitabine combination in pancreatic cancer.培美曲塞/吉西他滨联合用药治疗胰腺癌
Cancer. 2002 Aug 15;95(4 Suppl):928-32. doi: 10.1002/cncr.10755.
10
Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.培美曲塞用于经蒽环类药物、紫杉烷类药物和卡培他滨预处理的晚期乳腺癌患者的II期研究。
Clin Breast Cancer. 2005 Jun;6(2):143-9. doi: 10.3816/CBC.2005.n.016.

引用本文的文献

1
Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.通过表达4-1BBL和CD40L驱动免疫系统的两个轴来调节溶瘤腺病毒免疫疗法。
Hum Gene Ther. 2022 Mar;33(5-6):250-261. doi: 10.1089/hum.2021.197. Epub 2022 Jan 6.
2
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.奥沙利铂、亚叶酸钙和5-氟尿嘧啶用于吉西他滨预处理的晚期胰腺癌的二线治疗:一项II期研究。
Invest New Drugs. 2005 Aug;23(4):369-75. doi: 10.1007/s10637-005-1446-y.

本文引用的文献

1
Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.欧盟的癌症发病率和死亡率:癌症登记数据及1990年各国发病率估计值
Eur J Cancer. 1997 Jun;33(7):1075-107. doi: 10.1016/s0959-8049(96)00492-3.
2
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.吉西他滨作为晚期胰腺癌患者一线治疗方案在生存及临床获益方面的改善:一项随机试验
J Clin Oncol. 1997 Jun;15(6):2403-13. doi: 10.1200/JCO.1997.15.6.2403.
3
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.吉西他滨在人肿瘤克隆试验中的活性作为吉西他滨临床试验的基础。圣安东尼奥药物开发团队。
Invest New Drugs. 1996;14(3):265-70. doi: 10.1007/BF00194529.
4
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.吉西他滨用于5-氟尿嘧啶难治性胰腺癌患者的II期试验。
Ann Oncol. 1996 Apr;7(4):347-53. doi: 10.1093/oxfordjournals.annonc.a010600.
5
Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective.吉西他滨用于胰腺癌:寻找临床获益有多难?美国视角。
Ann Oncol. 1996 Apr;7(4):335-7. doi: 10.1093/oxfordjournals.annonc.a010597.
6
Phase II study of gemcitabine in patients with advanced pancreatic cancer.吉西他滨用于晚期胰腺癌患者的II期研究。
Br J Cancer. 1996 Jan;73(1):101-5. doi: 10.1038/bjc.1996.18.
7
Pancreatic cancer: how can we progress?胰腺癌:我们如何取得进展?
Eur J Cancer. 1993;29A(2):171-2. doi: 10.1016/0959-8049(93)90167-e.
8
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.吉西他滨连续5天静脉推注的I期临床试验。
Eur J Cancer. 1994;30A(3):417-8. doi: 10.1016/0959-8049(94)90276-3.
9
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.吉西他滨(2,2'-二氟脱氧胞苷)用于胰腺癌患者的II期试验。
Invest New Drugs. 1994;12(1):29-34. doi: 10.1007/BF00873232.
10
Should further studies of chemotherapy be carried out in pancreatic cancer?是否应该对胰腺癌进行进一步的化疗研究?
Eur J Cancer. 1993;29A(8):1076-8. doi: 10.1016/s0959-8049(05)80290-4.